logo
menu
01About us
Spin offCollaborationCILoacation
02Platforms
Ocular ImplantsMicroarray Patches
03Pipelines
SMO SeriesSMM SeriesSMZ Series
04Facilities
SMO LineSMM Line1st Site2nd Site
05Business
Business ModelCDMO Business
06News
NoticeIRPR
07Contact us
call@sminnovation.com
Home    >    Pipelines    >    SMZ SeriesSMZ Series

SMZ

SMZ1
SMZ2
SMZ3
SMZ4
image

SMZ1 Information

Indikation
AMD
Klassifizierung
Botanische Droge
Wirkstoff
Melissenblattextrakt
Verabreichungsart
Orale Verabreichung
Milestones
milestones
footer-logo
CEO : Jinha Park
Unternehmen : SANGMYUNG Innovation Co., Ltd.
Tel : +82 2 3489 6100
Hauptsitz : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republik Korea
Niederlassung Seoul : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republik Korea
DatenschutzrichtlinieCopyright © SANGMYUNG innovation